Colorectal cancer risk factors, risk prediction and blood-based biomarker by tumor consensus molecular subtype

按肿瘤共有分子亚型分类的结直肠癌危险因素、风险预测和血液生物标志物

• 批准号: 10021547
• 负责人: ROBERT S BRESALIER
• 金额: $ 39.22万
• 依托单位: UNIVERSITY OF TX MD ANDERSON CAN CTR
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-09-20 至 2022-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10021547
• 关键词: Adoption; Age; BRAF gene; Biological Assay; Biology; Blood; Cancer Biology; Cancer Burden; Characteristics; Clinical; Clinical Data; Clinical Trials; Colonoscopy; Colorectal Adenoma; Colorectal Cancer; Consensus; Data; Data Set; Detection; Development; Diagnosis; Disease; Early Diagnosis; Epidemiology; Feces; Future; Heterogeneity; Immune; Individual; Infiltration; International; KRAS2 gene; Knowledge; Left; Life Style; Location; Malignant Neoplasms; Mesenchymal; Metabolic; Methods; Microsatellite Instability; Modality; Modeling; Molecular; Morbidity - disease rate; Mutation; National Cancer Institute; Natural History; Neoplasms; Outcome; Patient-Focused Outcomes; Patients; Performance; Persons; Population; Prevention; Prevention strategy; Preventive Intervention; Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; RNA; Recommendation; Relapse; Resources; Risk; Risk Assessment; Risk Factors; Sampling; Sensitivity and Specificity; Serum; Side; Site; Smoking Status; Specificity; Specimen; Stage at Diagnosis; Techniques; Testing; Time; Transforming Growth Factor beta; Tumor Biology; Tumor Markers; Tumor Subtype; Tumor stage; Tumor-infiltrating immune cells; United States; Validation; Variant; Work; adenoma; angiogenesis; base; biomarker panel; blood-based biomarker; cancer biomarkers; cancer diagnosis; cancer subtypes; cohort; colorectal cancer risk; colorectal cancer screening; improved; interest; malignant breast neoplasm; molecular subtypes; mortality; nano-string; non-compliance; novel; patient screening; performance tests; profiles in patients; prospective; screening; screening guidelines; standard of care; tool; tumor; uptake

PLCO Project Summary Despite the availability of effective screening techniques, only 40% of colorectal cancer (CRC) cases are diagnosed at a localized stage of disease. This is likely due to a combination of factors, including screening non- compliance, limitations in the screening sensitivity and specificity, and heterogeneity of CRC biology. Specifically the existence of more aggressive tumor subtypes, which may have a shorter natural history, combined with screening inadequacies hinder our ability to detect more early stage disease and further reduce CRC morbidity and mortality. The recently described consensus molecular subtypes (CMS) of CRC include a more aggressive, mesenchymal subtype and provide a framework for stratified risk assessment, screening recommendations and prevention interventions. The four subtypes identified have distinct biology and clinical outcomes, suggesting the possibility of unique risk factors, prevention, and screening strategies. Specifically, CMS1 (Immune, 14% of cases) is associated with high micro-satellite instability (MSI), BRAF mutations and immune infiltration, CMS2 (Canonical, 37%) accounts for the largest percent of tumors and is characterized by activation of WNT and MYC, CMS3 (Metabolic, 13%) is characterized by low somatic copy number alterations, KRAS mutations and tumor metabolic dysregulation, CMS4 (Mesenchymal, 23%) is characterized by stromal infiltration, TGF-β activation, angiogenesis and worse overall and relapse-free survival (Nat Med. 2015, 21:1350). The studies in this proposal utilize the CMS framework to develop and test a risk-prediction tool and test the CMS-specific performance of a validated blood-based three-marker panel. Building on our preliminary data and using the high-quality, longitudinal data and tumor RNA from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, we plan to test the associations of CMS with age, smoking status, and tumor stage at diagnosis (Aim 1). Using the associations from aim 1, we plan to build and test a CMS-specific CRC risk prediction tool to facilitate screening and prevention efforts (Aim 2). We also plan to further test the performance of our validated blood-based three-marker panel across CMS and in the years prior to diagnosis (Aim 3). The combination of a CMS-specific risk prediction tool and a validated blood-based biomarker has the potential to greatly improve CRC screening compliance and early detection, leading to a reduction in morbidity and mortality from CRC.

PLCO项目摘要 尽管有效筛查技术可用，但只有40％的大肠癌（CRC）病例是 在疾病的局部阶段诊断。这可能是由于因素的组合，包括筛查非 - CRC生物学的合规性，筛选灵敏度和特异性的局限性以及异质性。具体来说 可能具有更短的自然历史的更具侵略性的肿瘤亚型的存在，并结合 筛选不足阻碍了我们发现更多早期疾病并进一步降低CRC发病率的能力 和死亡率。 最近描述的CRC的共有分子亚型（CMS）包括更具侵略性的，更具侵略性的 间充质亚型，并为分层风险评估，筛选建议和 预防干预措施。确定的四个亚型具有不同的生物学和临床结果，表明 独特的风险因素，预防和筛查策略的可能性。具体而言，CMS1（免疫，14％ 病例）与高微卫星不稳定性（MSI），BRAF突变和免疫浸润有关，CMS2 （规范，37％）占肿瘤百分比最大，其特征是激活Wnt和Myc， CMS3（代谢，13％）的特征是较低的体细胞拷贝数改变，KRAS突变和肿瘤 代谢失调，CMS4（间充质，23％）的特征是基质浸润，TGF-β激活， 血管生成，整体和无救生生存率较差（Nat Med。2015，21：1350）。该提议中的研究 利用CMS框架开发和测试风险预测工具并测试一个特定于CMS的性能 经过验证的血液三标记面板。 以我们的初步数据为基础，并使用来自的高质量，纵向数据和肿瘤RNA 前列腺，肺，结直肠癌和卵巢癌筛查试验，我们计划测试CMS的关联 诊断时的年龄，吸烟状况和肿瘤阶段（AIM 1）。使用AIM 1的协会，我们计划建立 并测试CMS特异性的CRC风险预测工具，以促进筛查和预防工作（AIM 2）。我们也是 计划进一步测试我们在CMS和 诊断前几年（AIM 3）。 CMS特异性风险预测工具和经过验证的血液生物标志物的组合具有 大大提高CRC筛选依从性和早期检测的潜力，导致发病率降低 和CRC的死亡率。